Prosocial polio vaccination in Israel.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
09 06 2020
Historique:
pubmed: 28 5 2020
medline: 22 8 2020
entrez: 28 5 2020
Statut: ppublish

Résumé

Regions with insufficient vaccination have hindered worldwide poliomyelitis eradication, as they are vulnerable to sporadic outbreaks through reintroduction of the disease. Despite Israel's having been declared polio-free in 1988, a routine sewage surveillance program detected polio in 2013. To curtail transmission, the Israel Ministry of Health launched a vaccine campaign to vaccinate children-who had only received the inactivated polio vaccine-with the oral polio vaccine (OPV). Determining the degree of prosocial motivation in vaccination behavior is challenging because vaccination typically provides direct benefits to the individual as well as indirect benefits to the community by curtailing transmission. However, the Israel OPV campaign provides a unique and excellent opportunity to quantify and model prosocial vaccination as its primary objective was to avert transmission. Using primary survey data and a game-theoretical model, we examine and quantify prosocial behavior during the OPV campaign. We found that the observed vaccination behavior in the Israeli OPV campaign is attributable to prosocial behavior and heterogeneous perceived risk of paralysis based on the individual's comprehension of the prosocial nature of the campaign. We also found that the benefit of increasing comprehension of the prosocial nature of the campaign would be limited if even 24% of the population acts primarily from self-interest, as greater vaccination coverage provides no personal utility to them. Our results suggest that to improve coverage, communication efforts should also focus on alleviating perceived fears surrounding the vaccine.

Identifiants

pubmed: 32457142
pii: 1922746117
doi: 10.1073/pnas.1922746117
pmc: PMC7293608
doi:

Substances chimiques

Poliovirus Vaccine, Inactivated 0
Poliovirus Vaccine, Oral 0
Sewage 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13138-13144

Informations de copyright

Copyright © 2020 the Author(s). Published by PNAS.

Déclaration de conflit d'intérêts

Competing interest statement: C.C.-C. and A.P.G. are co-Principal Investigators on a multiinstitution grant. They are not collaborating directly.

Références

Vaccine. 2011 Oct 26;29(46):8205-14
pubmed: 21896299
Gynecol Oncol. 2009 Mar;112(3):577-82
pubmed: 19150120
Sci Rep. 2015 Jun 02;5:10724
pubmed: 26035413
J Infect Dis. 2014 Nov 1;210 Suppl 1:S540-6
pubmed: 25316878
Vaccine. 2010 Jun 11;28(26):4235-48
pubmed: 20438879
PLoS One. 2016 Jul 26;11(7):e0159780
pubmed: 27459237
PLoS Biol. 2005 Jun;3(6):e194
pubmed: 15941355
Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5692-7
pubmed: 17369367
PLoS Pathog. 2012;8(4):e1002599
pubmed: 22532797
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Malar J. 2018 Apr 27;17(1):179
pubmed: 29703192
Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10625-E10633
pubmed: 30337479
Euro Surveill. 2014 Feb 20;19(7):20703
pubmed: 24576475
MMWR Morb Mortal Wkly Rep. 2016 May 13;65(18):470-3
pubmed: 27171208
J R Soc Interface. 2012 Sep 7;9(74):2234-43
pubmed: 22496100
Lancet Infect Dis. 2015 Oct;15(10):1236-1242
pubmed: 26213249
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10564-7
pubmed: 12920181
Soc Cogn Affect Neurosci. 2017 Aug 1;12(8):1219-1228
pubmed: 28402506
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
AJS. 1966 Jan;71(4):407-16
pubmed: 5951757
Vaccine. 2011 Dec 30;29 Suppl 4:D80-5
pubmed: 22486981
Euro Surveill. 2013 Sep 19;18(38):
pubmed: 24084337
Nature. 2006 Aug 24;442(7105):912-5
pubmed: 16929297
Lancet Infect Dis. 2019 Apr;19(4):392-401
pubmed: 30938299
BMC Med. 2016 Jun 23;14(1):95
pubmed: 27334457
Bull Math Biol. 2007 Jul;69(5):1453-76
pubmed: 17235708
Health Psychol. 2013 Sep;32(9):978-85
pubmed: 24001248
Bull World Health Organ. 2007 Jun;85(6):487-92
pubmed: 17639247
Proc Biol Sci. 2014 Feb 12;281(1780):20133172
pubmed: 24523276
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):1593-1598
pubmed: 29378938
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13391-4
pubmed: 15329411
Int J Infect Dis. 2014 Jan;18:4-13
pubmed: 24246740
BMC Med. 2016 Mar 14;14:43
pubmed: 26971523

Auteurs

Chad R Wells (CR)

Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT 06520.

Amit Huppert (A)

The Biostatistics & Biomathematics Unit, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, 52621 Ramat Gan, Israel.
School of Public Health, The Sackler Faculty of Medicine, Tel-Aviv University, 69978 Tel Aviv, Israel.

Meagan C Fitzpatrick (MC)

Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT 06520.
Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD 21201.

Abhishek Pandey (A)

Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT 06520.

Baruch Velan (B)

The Biostatistics & Biomathematics Unit, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Tel Hashomer, 52621 Ramat Gan, Israel.

Burton H Singer (BH)

Emerging Pathogens Institute, University of Florida, Gainesville, FL 32610; bhsinger@epi.ufl.edu.

Chris T Bauch (CT)

Department of Applied Mathematics, University of Waterloo, Waterloo, ON N2L 3G1, Canada.

Alison P Galvani (AP)

Center for Infectious Disease Modeling and Analysis, Yale School of Public Health, New Haven, CT 06520.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH